Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of March 2014. The report documents the results of a Special General Meeting of Shareholders held on March 11, 2014, at the company's principal executive offices in Rehovot, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance proceedings rather than financial performance data.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this document. The primary event reported is the successful approval of shareholder proposals.
Guidance, Outlook, and Management Commentary
At the Special General Meeting, a quorum was present, and each proposal on the agenda was duly approved. Details regarding the specific proposals are referenced in the Company's proxy statement filed on February 10, 2014 (Exhibit 99.1). The filing includes a notice announcing the results of the meeting as Exhibit 99.1.
Important Facts for Investors to Verify
- Review the proxy statement filed on February 10, 2014, to understand the specific content of the approved shareholder proposals.
- Confirm the details of the meeting results in Exhibit 99.1 attached to this filing.
- Note that this filing contains no financial data; refer to the most recent Form 20-F for financial metrics.